Matthew Akiyama is an Infectious Disease physician affiliated with Albert Einstein College of Medicine. OpenAlex indexes 141 publications with 1,982 citations (h-index 25); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1621 Eastchester Rd
Bronx, NY 104612604
Telephone
718-405-8004Registry record last updated 23 Jan 2018.
Clinical trials
- Leveraging CHWs to Improve COVID-19 Testing and Mitigation Among CJIs Accessing a Corrections-focused CBO
Sponsor: Montefiore Medical Center
- Advanced Care Coordination and Enhanced Linkage and Retention Among Transitional Re-Entrants
Sponsor: Montefiore Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202510 payments
- GlaxoSmithKline, LLC.Program year20252 payments
- ABBVIE INC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
28.2%Statin13.4%Atorvastatin Calcium84%Pravastatin Sodium16%Part D<11 patientsBeta blocker3.9%Metoprolol Succinate55%Atenolol46%Part D<11 patients+ 5 more classes in this area
Anti-infectives
26.2%Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor10.4%Tivicay50%Dovato36%Cabenuva14%Part D<11 patientsHuman Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor6.9%Triumeq79%Descovy21%Part D<11 patients+ 4 more classes in this area
Metabolism & gastrointestinal
17.7%Insulin Analog5.5%Basaglar Kwikpen U-10026%Novolog Flexpen26%Lantus Solostar24%Tresiba Flextouch U-20024%Part D<11 patientsGLP-1 receptor agonist5.2%Ozempic55%Trulicity46%Part D<11 patients+ 5 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 2017–2026 per NIH RePORTER. The latest:
- A Decentralized, Status neutral, Stakeholder-engaged, post-incarceration intervention for people with and at risk for HIV
Albert Einstein College of Medicine
FY2026$1,231,968R33DA060627 - Leveraging community health workers to improve SARS-CoV-2 testing and mitigation among criminal justice-involved individuals accessing a corrections-focused community-based organization
Albert Einstein College of Medicine
FY2026$653,168R01MD016744 - Mentoring investigators to improve health outcomes among people with HIV and HCV
Albert Einstein College of Medicine
FY2026$192,305K24MD021876
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Best practice guidelines for viral hepatitis service delivery in prisons
The Lancet Infectious Diseases
2025 - Barriers and advocacy needs for hepatitis C services in prisons: Informing the prisons hepatitis C advocacy toolkit
International Journal of Drug Policy
2024 - Estimates of Hepatitis C Seroprevalence and Viremia in State Prison Populations in the United States
The Journal of Infectious Diseases
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Lipton, MD
Albert Einstein College of Medicine
Marina Konopleva, MD, PhD
Albert Einstein College of Medicine
Jill Crandall, MD
Albert Einstein College of Medicine
Ira Sussman, MD
Albert Einstein College of Medicine
Thomas Walsh, MD
Cornell University
Vance Fowler, MD
Duke University
Myron Cohen, MD
University of North Carolina at Chapel Hill School of Medicine
Derrick W. Crook
John Radcliffe Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”